Mirati Therapeutics, Inc. (NASDAQ:MRTX)’s share price shot up 6.7% during mid-day trading on Monday . The stock traded as high as $25.20 and last traded at $24.75. 955,000 shares changed hands during trading, an increase of 96% from the average session volume of 488,300 shares. The stock had previously closed at $23.20.

Several brokerages have recently issued reports on MRTX. BidaskClub upgraded Mirati Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday. HC Wainwright boosted their price objective on Mirati Therapeutics from $17.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday, January 9th. Oppenheimer set a $18.00 price objective on Mirati Therapeutics and gave the stock a “buy” rating in a research report on Monday, January 8th. Cann reiterated a “buy” rating and set a $18.00 price objective on shares of Mirati Therapeutics in a research report on Monday, January 8th. Finally, Cowen began coverage on Mirati Therapeutics in a research report on Thursday, December 21st. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $14.75.

The company has a market capitalization of $668.09, a PE ratio of -7.80 and a beta of 1.61.

Mirati Therapeutics (NASDAQ:MRTX) last released its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.16. equities research analysts anticipate that Mirati Therapeutics, Inc. will post -2.73 EPS for the current year.

In other Mirati Therapeutics news, SVP Jamie Christensen sold 14,725 shares of the company’s stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $22.99, for a total value of $338,527.75. Following the transaction, the senior vice president now owns 6,395 shares of the company’s stock, valued at $147,021.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Venbio Select Advisor Llc purchased 650,000 shares of the company’s stock in a transaction on Thursday, November 16th. The stock was bought at an average cost of $13.00 per share, for a total transaction of $8,450,000.00. The disclosure for this purchase can be found here. Insiders sold 32,499 shares of company stock valued at $628,464 over the last 90 days. 5.10% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC bought a new position in shares of Mirati Therapeutics in the third quarter valued at $268,000. OxFORD Asset Management LLP bought a new position in shares of Mirati Therapeutics in the third quarter valued at $365,000. Susquehanna International Group LLP increased its holdings in shares of Mirati Therapeutics by 46.5% in the second quarter. Susquehanna International Group LLP now owns 50,509 shares of the biotechnology company’s stock valued at $184,000 after buying an additional 16,030 shares in the last quarter. PDT Partners LLC bought a new position in shares of Mirati Therapeutics in the second quarter valued at $200,000. Finally, Jane Street Group LLC bought a new position in shares of Mirati Therapeutics in the third quarter valued at $668,000. 64.68% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was published by Daily Political and is the sole property of of Daily Political. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.dailypolitical.com/2018/01/17/mirati-therapeutics-mrtx-shares-up-6-7.html.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.